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Abstract
Introduction: A product recall was issued for the Roche/Hitachi Cobas Gentamicin II assays on 25th May 2016 in Australia, after a 15 - 20% positive 
analytical shift was discovered. Laboratories were advised to employ the Thermo Fisher Gentamicin assay as an alternative. Following the reintro-
duction of the revised assay on 12th September 2016, a second reagent recall was made on 20th March 2017 after the discovery of a 20% negative 
analytical shift due to erroneous instrument adjustment factor. 
Materials and methods: The practices of an index laboratory were examined to determine how the analytical shifts evaded detection by routine 
internal quality control (IQC) and external quality assurance (EQA) systems. The ability of the patient result-based approaches, including moving 
average (MovAvg) and moving sum of outliers (MovSO) approaches in detecting these shifts were examined. 
Results: Internal quality control data of the index laboratory were acceptable prior to the product recall. The practice of adjusting IQC target 
following a change in assay method resulted in the missed negative shift when the revised Roche assay was reintroduced. While the EQA data of the 
Roche subgroup showed clear negative bias relative to other laboratory methods, the results were considered as possible ‘matrix effect’. The Mo-
vAvg method detected the positive shift before the product recall. The MovSO did not detect the negative shift in the index laboratory but did so in 
another laboratory 5 days before the second product recall. 
Conclusions: There are gaps in current laboratory quality practices that leave room for analytical errors to evade detection. 
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Laboratory analytical performance (precision and 
accuracy) is monitored routinely by a combination 
of internal quality control (IQC) and external quali-
ty assurance (EQA) activities. The IQC system in-
volves periodic measurement of a set of QC sam-
ples at different concentrations and comparing 
these results against predefined control limits. It is 
aimed at providing a snapshot of the assay perfor-
mance at the time of measurement to assist in the 
decision to make available results produced by the 
assay. On the other hand, a set of EQA materials is 
circulated and measured by a group of participat-
ing laboratories to promote transportability of re-
sults. It is important to note that IQC and EQA are 
not generally designed to monitor trueness. 
Despite these quality systems, clinically significant 
changes in analytical performance can occur and 
yet evade detection by the laboratory. This may be 
due to the episodic nature of these quality sys-
tems, the use of inappropriate QC sample concen-
trations, the use of underpowered statistical tech-
niques, or the presence of so called matrix effects 
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in the materials used in IQC or EQA that may not 
fully represent the patient samples (1-4). Such sig-
nificant shift or drift in analytical performance can 
occur during reagent lot change, and can cause an 
assay to report falsely high or low results.
Gentamicin is an aminoglycoside antibiotic com-
monly used for treatment of bacterial infections. It 
has a narrow therapeutic range. When the serum 
gentamicin concentration is within the toxicity 
range, it increases the risk of adverse effects such 
as impaired hearing and renal function. The renal 
impairment is generally reversible while hearing 
impairment can be permanent (5). A product recall 
was issued for the Roche/Hitachi Cobas Gen-
tamicin II assays (Roche Diagnostics, Mannheim, 
Germany) on 25th May 2016 in Australia, after a 15 
- 20% positive analytical shift was reported (6). 
In this report, we reviewed the practices of an in-
dex laboratory to examine how this analytical shift 
can evade detection by routine IQC and EQA sys-
tems in the Roche/Hitachi Cobas Gentamicin II as-
says, and examined the ability of the patient re-
sult-based approaches, including moving average 
(MovAvg) and the more recently described mov-
ing sum of outliers (MovSO) approaches in detect-
ing this shift (2,7). 
Materials and methods
GENT2 product recalls 
The Roche Cobas GENT2 assay (Roche Diagnostics, 
Mannheim, Germany) is a one-step competitive ki-
netic interaction of microparticles in a solution im-
munoassay, and has been in use in the index labo-
ratory since 2013. On 25th May 2016, Roche issued 
an advisory to their GENT2 assay users of an in-
creased recovery of 15 - 20% in patient results and 
initiated a reagent recall (for Cobas 701/702: part 
number: 05841291190, reagent lot numbers: 
119167, 611783, 617624; for Cobas 501/502: part 
number 04490843190, reagent lot numbers: 
119166, 611780, 617623). The assay was reinstated 
September 2016 with a recommended instrument 
adjustment factor of 0.8 to account for ‘calibrator 
matrix issue’. On 20th Mar 2017, another product 
recall for the Roche GENT2 assay was issued by the 
Therapeutic Goods Administration (Australia) for 
erroneous instrument adjustment factor that was 
inappropriately low, leading to under-recovery of 
patient results. The sequence of events involving 
the analytical product recalls is summarized in Ta-
ble 1. Of note, assay performance verification and 
comparison exercises were performed internally 
by the laboratory prior to routine implementation 
in compliance with the regulations of National As-
sociation of Testing Authorities, Australia. 
Missed detection by internal quality control 
procedure
At the index laboratory, the Chemtrak QC levels 1 
and 3 (Thermo Fisher, San Jose, USA) for gen-
tamicin were used. The targets for the QC material 
were established internally by the laboratory (for 
level 1: target 6.76 (standard deviation (SD) 0.21) 
mg/L; for level 3: target 1.56 (SD 0.06) mg/L). The 
mean values for the IQC samples used in the con-
Date Event
17th May 2016 Roche advised of stock supply issues with GENT2 assay
25th May 2016
Roche advised of increased recovery of 
patient results and reagent recall. Advised 
use of alternate assay.
31st May 2016 Cessation of Roche assay
1st Jun 2016 Switched to Thermo Fisher Gentamicin reagent
12th Sep 2016
Roche advised GENT2 assay now available 
again but with 0.8 instrument adjustment 
factor due to ‘calibrator matrix issue’
20th Oct 2016
Revised Roche assay with instrument 
adjustment factor of 0.8 reintroduced into 
clinical service
20th Mar 2017
Therapeutic Goods Administration 
(Australia) recalled Roche GENT2 assay due 
to decreased patient recovery (Reference 
RC-2017-RN-00374-1). Instrument adjustment 
factor of 0.8 recommended by Roche was 
inappropriately low and laboratory was 
advised to reset instrument adjustment 
factor to 1.
24th Mar 2017 Laboratory decided to reintroduce the Thermo Fisher Gentamicin reagent
Table 1. Sequence of events leading to the discovery of the an-
alytical shift in the gentamicin assay at the laboratory reviewed
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trol chart are verified with each reagent/IQC lot 
change by measuring several replicates of IQC 
samples. This was performed most recently in Jan-
uary 2016 when there was an IQC lot change. The 
mean (target) value is changed, if the average re-
sult of the IQC samples using the new lot differs 
significantly (larger than the allowable limit of per-
formance set by the Royal College of Pathologists 
of Australasia Quality Assurance Programme (RC-
PAQAP)) from the in-use reagent lot and the EQA 
results are acceptable. This procedure is undertak-
en to account for any lot-specific changes that may 
affect measurement of IQC materials secondary to 
matrix-related (commutability) issues. The assay 
capability (as determined by sigma metrics) is con-
tinuously monitored and the IQC control limits 
may be widened and reduced depending on the 
performance (standard deviation of IQC samples) 
of the assay. 
During the time before the first reagent recall (i.e. 
prior to 25th May 2016), the IQC did not detect any 
significant analytical shift, defined as any violation 
of the 2:2S, 1:3S or 4:1S rules (Figure 1, upper pan-
el). On the other hand, when the laboratory rein-
troduced the revised GENT2 assay with an instru-
ment adjustment factor of 0.8, there were indica-
tions of negative bias with multiple lower control 
limit violation (Figure 1, lower panel). However, be-
cause the index laboratory was using narrower 
control limits that were adapted from the Thermo 
Fisher assay while monitoring the capability of the 
revised GENT2 assay before deciding whether to 
widen them, these violations were placed on 
watching brief. 
Figure 1. Internal quality control (IQC) data of the index laboratory. The upper panel shows the IQC chart showing acceptable results 
up to the 1st Roche GENT2 reagent recall secondary to a 15 - 20% positive bias. The lower panel shows the IQC data during the use of 
the revised Roche assay with a 20% negative bias. The areas shaded light grey and grey represent 2 - 3 standard deviations and > 3 
standard deviations, respectively. 
IQC chart when Thermo Fisher 
assay was used as replacement
IQC chart following reintroduction of 
revised GENT2 assay
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Missed detection by external quality 
assurance programme
In the RCPAQAP, the peer performance of gen-
tamicin assays is compared against the median re-
sults of the method subgroups. For the index labo-
ratory, the gentamicin assay performed within ac-
ceptable limits during the affected period when 
compared to the other peer laboratories using the 
same affected reagents (Figure 2). However, the 
Roche Cobas subgroup showed a clear bias when 
compared to other laboratory methods. Owing to 
commutability considerations, it is probable that 
the laboratories using the affected reagent lot 
only interpreted their results using their peer 
group results and did not consider their difference 
to other laboratory methods as significant. Similar-
ly, there was an excessive negative bias detected 
in the Roche peer subgroup following the change 
to the revised assay.  
Use of ‘moving statistics’ techniques for 
analytical shift detection
Given the above limitations of the routine quality 
systems, the ability of ‘moving statistics’ such as 
the MovAvg and the MovSO techniques in detect-
ing the analytical shifts was examined. For this 
study, laboratory results for gentamicin between 
1st January 2015 and 5th April 2017 were extracted 
from the laboratory information system. 
Figure 2. Analytical shift missed by the external quality assurance programme before the second reagent recall secondary to the 
presence of a negative bias, as the peer laboratories against which the index laboratory was compared were similarly using the af-
fected reagents. 
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Moving average
The MovAvg control chart was constructed as pre-
viously described (2). Briefly, laboratory results be-
tween 1st January 2015 and 30th June 2015 were 
taken as the analytically stable period, as evi-
denced by stable IQC and EQA performances. The 
data were used to calculate the population mean 
and standard deviation. Next we calculated the 
moving average of the block for the data from 1st 
July 2015 to 5th April 2017. A truncation limit of 5.0 
mg/L was applied, which removed 4.4% of the 
overall data. The truncation limit was applied to 
remove extreme values (‘outliers’), which may 
skew the moving average. The removal of 4.4% of 
data using the truncation limit is within the recom-
mended outlier removal as a proportion of the 
overall data of 20% (8). The upper and lower con-





A block size of 100 was used for all the calculations 
in this study. A result that is below the detection 
limit (i.e. < 0.4 mg/L) was considered as 0.2 mg/L 
for the purpose of calculating the moving average. 
This assumption is acceptable in this scenario since 
at shift of 15 - 20% is too small to trigger the con-
trol limits. A MovAvg control chart was construct-
ed by applying the population mean and control 
limits on the remaining gentamicin data from 1st 
July 2015 to 5th April 2017. An analytical error is de-
tected when the moving average violates any of 
the control limits. 
Moving sum of outliers 
The MovSO control chart was constructed as re-
cently described (7). Briefly, laboratory results from 
the stable period, as defined above, were used to 
derive the mean and SD of the number of outlier 
results, which was defined as any laboratory re-
sults that was above 1.0 mg/L (the cut-off value 
used by the laboratory). The upper and lower con-
trol limits were set as mean ± 3 × SD, respectively. 
A MovSO control chart was constructed by apply-
ing the mean and control limits on the remaining 
gentamicin data from 1st July 2015 to 5th April 2017. 
An analytical error is detected when the moving 
average violates any of the control limits. To con-
firm the findings, the same moving statistic tech-
niques were applied to another laboratory (labora-
tory W) that was also using the Roche GENT2 assay 
within the same pathology network.
Results
The results of the moving statistics are shown in 
Figures 3 and 4. The MovAvg technique first de-
tected a positive shift in patient results on 20th 
March 2016 while the MovSO detected a positive 
shift seven days earlier on 13th March 2016. The 
MovAvg detected a positive bias on 13th Novem-
ber 2015 at laboratory W. On the other hand, the 
MovSO detected a positive bias and a negative 
bias on 9th January 2016 and 15th March 2017 at 
laboratory W, respectively (Figures 3 and 4).
Clinical impact
Additionally, consultation with both adult and 
child physicians was undertaken facilitated by the 
Clinical Excellence Commission, New South Wales, 
Australia. A retrospective clinical review was un-
dertaken for both children and adults. The retro-
spective clinical review was for 12 months. The 
number of adults was restricted to those with mul-
tiple measurements within the episode of hospi-
talisation. The children retrospective review was 
based on the result concentration between 1.2 
and 2.0 mg/L. Whilst there was a number of pa-
tients that fell into these categories, to date the 
physicians have reported no adverse effects.
Discussion
There is accumulating evidence to show that the 
traditional quality control systems in routinely lab-
oratory practice are inadequate to detect error in 
the increasingly complex testing environment 
(4,7). This is further confounded by the use of arti-
ficial IQC and EQA sample materials that may not 
fully represent patient samples. Laboratory staff 
often mistake shifts in a method group median as 
a matrix effect when it may represent a true bias in 
a method caused by a change in calibrator value 
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Figure 4. Moving sum of outlier control chart of gentamicin from 1st July 2015 to 5th April 2017 for the index laboratory (upper pan-
el) and laboratory W (lower panel). A result of > 5.0 mg/L was considerd as an outlier. The horizontal lines represented the upper and 
lower control limits, respectively. 
Figure 3. Moving average control chart of gentamicin from 1st July 2015 to 5th April 2017 for the index laboratory (upper panel) and 
laboratory W (lower panel). The horizontal lines represent the upper and lower control limits, respectively. 
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or reagent reformulation. Relative changes in bias 
between different method subgroups should al-
ways be investigated particularly with assays that 
have been used for long periods. If the laboratory 
incorrectly assumes this shift is a matrix effect they 
may introduce post analytical factors such as the 
adjustment of IQC control chart mean / target val-
ue or EQA peer group comparison by median / 
mean. As illustrated in this report, these can have 
the unintended consequence of confounding the 
interpretation of the quality control data and miss-
ing an error the quality systems was designed to 
detect. Of note, there were 10 IQC rule violations 
prior to the first product recall but this rule was 
generally considered a ‘warning’ flag by the index 
laboratory and they ‘self-resolved’ upon further 
testing. This represents another missed opportu-
nity for earlier error detection.
On the other hand, the use of moving statistics is 
an important tool to improve error detection in 
modern laboratories. They have been shown to 
out-perform traditional IQC approaches in detect-
ing analytical shift, even at low analyte concentra-
tions (2,7). The MovAvg technique is suitable for 
detecting large analytical shifts, whereas the Mov-
SO is particularly suitable for detecting critical 
shifts at low concentrations that affects the classi-
fication of patient results (7). In this instance, the 
MovSO technique had very comparable perfor-
mance to the MovAvg technique. 
The main advantage of using moving statistics is 
that the analytical performance is monitored by 
actual patient results generated from clinical sam-
ples that the analytical system is designed to 
measure. However, these statistical techniques re-
main unfamiliar to many laboratory practitioners. 
Another barrier to practice is the relatively limited 
laboratory information systems that may not allow 
easy extraction and manipulation of patient re-
sults for the purpose of constructing these control 
charts. 
Importantly, the moving statistics did not detect 
the 20% negative bias associated with the errone-
ous instrument adjustment factor of 0.8 that trig-
gered the second reagent recall, except the Mov-
SO when applied on laboratory W. This may be ex-
plained by the relatively wide control limits com-
pared to the analytical shift. For example, the 
three standard deviations represented 40% and 
50% of the mean (or central value) of the MovAvg 
and MovSO control charts of the index laboratory, 
respectively; and 15% and 21% of Laboratory W, 
respectively. This underscores the fact that the 
performance of the moving statistics is highly de-
pendent on the variability of the underlying popu-
lation being monitored since the patient and the 
analytical method contribute any observed varia-
tion (8,9). For a therapeutic drug monitoring test, 
the variability of the population result is likely to 
be high since it is not a physiologically tightly con-
trolled substance. Additionally, there is a lag effect 
of using moving statistics, where an analytical shift 
needs to affect a relatively large number of patient 
results before the moving statistics can violate the 
control limit. One possible way to overcome this 
limitation may be to pool the laboratory data from 
multiple sites to increase the number of results. 
However, this is limited by the need for the differ-
ent laboratories to be using the same reagent lot 
to maximize the statistical power. 
This report illustrated the short coming of some of 
the common laboratory quality systems in detect-
ing an analytical shift and also provided evidence 
that additional patient-based laboratory statistics 
is needed to optimise the risk management of lab-
oratory errors. EQA providers have a role in this 
challenge by providing simple tools that allow a 
laboratory to identify significant changes in lot cal-
ibration by a manufacturer relative to other manu-
facturers or same manufacturer lots. However few 
EQA providers do that currently.
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